View Item 

Show simple item record

Review article: current and emerging therapies for functional dyspepsia

dc.contributor.authorSaad, Richard J.en_US
dc.contributor.authorChey, William D.en_US
dc.date.accessioned2010-06-01T21:47:40Z
dc.date.available2010-06-01T21:47:40Z
dc.date.issued2006-08en_US
dc.identifier.citationSAAD, R. J.; CHEY, W. D. (2006). "Review article: current and emerging therapies for functional dyspepsia." Alimentary Pharmacology & Therapeutics 24(3): 475-492. <http://hdl.handle.net/2027.42/74835>en_US
dc.identifier.issn0269-2813en_US
dc.identifier.issn1365-2036en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/74835
dc.identifier.urihttp://www.ncbi.nlm.nih.gov/sites/entrez?cmd=retrieve&db=pubmed&list_uids=16886913&dopt=citationen_US
dc.format.extent186193 bytes
dc.format.extent3109 bytes
dc.format.mimetypeapplication/pdf
dc.format.mimetypetext/plain
dc.publisherBlackwell Publishing Ltden_US
dc.rights2006 The Authors Journal compilation 2006 Blackwell Publishing Ltden_US
dc.titleReview article: current and emerging therapies for functional dyspepsiaen_US
dc.typeArticleen_US
dc.subject.hlbsecondlevelOtolaryngologyen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.identifier.pmid16886913en_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/74835/1/j.1365-2036.2006.03005.x.pdf
dc.identifier.doi10.1111/j.1365-2036.2006.03005.xen_US
dc.identifier.sourceAlimentary Pharmacology & Therapeuticsen_US
dc.identifier.citedreferenceTalley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. In: Drossman DA, ed. Rome II: the Functional Gastrointestinal Disorders. McLean, VA, USA: Degnon, 2000: 299 – 350.en_US
dc.identifier.citedreferenceTalley NJ, Vakil NB, Moayyedi P. American gastroenterological association technical review on the evaluation of dyspepsia. Gastroenterology 2005; 129: 1756 – 80.en_US
dc.identifier.citedreferenceTalley NJ, Stanghellini V, Heading RC, Koch KL, Malagelada JR, Tytgat GN. Functional gastroduodenal disorders. Gut 1999; 45 ( Suppl. 2 ): II37 – 42.en_US
dc.identifier.citedreferenceShaib Y, El-Serag HB. The prevalence and risk factors of functional dyspepsia in a multiethnic population in the United States. Am J Gastroenterol 2004; 99: 2210 – 6.en_US
dc.identifier.citedreferenceEl-Serag HB, Talley NJ. Systemic review: The prevalence and clinical course of functional dyspepsia. Aliment Pharmacol Ther 2004; 19: 643 – 54.en_US
dc.identifier.citedreferenceChang L. Review article: Epidemiology and quality of life in functional gastrointestinal disorders. Aliment Pharmacol Ther 2004; 20 ( Suppl. 7 ): 31 – 9.en_US
dc.identifier.citedreferenceHeikkinen M, Pikkarainen P, Takala J, Rasanen H, Julkunen R. Etiology of dyspepsia: four hundred unselected consecutive patients in general practice. Scand J Gastroenterol 1995; 30: 519 – 23.en_US
dc.identifier.citedreferenceMitchell CM, Drossman DA. Survey of the AGA membership relating to patients with functional gastrointestinal disorders. Gastroenterology 1987; 92 ( 5 Pt 1 ): 1282 – 4.en_US
dc.identifier.citedreferenceHeikkinen M, Farkkila M. What is the long-term outcome of the different subgroups of functional dyspepsia ? Aliment Pharmacol Ther 2003; 18: 223 – 9.en_US
dc.identifier.citedreferenceAgreus L, Svardsudd K, Talley NJ, Jones MP, Tibblin G. Natural history of gastroesophageal reflux disease and functional abdominal disorders: a population-based study. Am J Gastroenterol 2001; 96: 2905 – 14.en_US
dc.identifier.citedreferenceCorsetti M, Caenepeel P, Fischler B, Janssens J, Tack J. Impact of coexisting irritable bowel syndrome on symptoms and pathophysiological mechanisms in functional dyspepsia. Am J Gastroenterol 2004; 99: 1152 – 9.en_US
dc.identifier.citedreferenceCremonini F, Talley NJ. Review article: The overlap between functional dyspepsia and irritable bowel syndrome – a tale of one or two disorders ? Aliment Pharmacol Ther 2004; 20 ( Suppl. 7 ): 40 – 9.en_US
dc.identifier.citedreferenceQuigley EM. Functional dyspepsia (FD) and non-erosive reflux disease (NERD): overlapping or discrete entities ? Best Pract Res Clin Gastroenterol 2004; 18: 695 – 706.en_US
dc.identifier.citedreferenceLocke GR III, Weaver AL, Melton LJ III, Talley NJ. Psychosocial factors are linked to functional gastrointestinal disorders: a population based nested case-control study. Am J Gastroenterol 2004; 99: 350 – 7.en_US
dc.identifier.citedreferencePajala M, Heikkinen M, Hintikka J. Mental distress in patients with functional or organic dyspepsia: a comparative study with a sample of the general population. Aliment Pharmacol Ther 2005; 21: 277 – 81.en_US
dc.identifier.citedreferenceJones MP, Sharp LK, Crowell MD. Psychosocial correlates of symptoms in functional dyspepsia. Clin Gastroenterol Hepatol 2005; 3: 521 – 8.en_US
dc.identifier.citedreferenceNyren O, Lindberg G, Lindstrom E, Marke LA, Seensalu R. Economic costs of functional dyspepsia [see comments]. Pharmacoeconomics 1992; 1: 312 – 24.en_US
dc.identifier.citedreferenceHalder SL, Locke GR III, Talley NJ, Fett SL, Zinsmeister AR, Melton LJ III. Impact of functional gastrointestinal disorders on health-related quality of life: a population-based case-control study. Aliment Pharmacol Ther 2004; 19: 233 – 42.en_US
dc.identifier.citedreferenceKoloski NA, Talley NJ, Boyce PM. The impact of functional gastrointestinal disorders on quality of life. Am J Gastroenterol 2000; 95: 67 – 71.en_US
dc.identifier.citedreferenceTalley NJ, Weaver AL, Zinsmeister AR. Impact of functional dyspepsia on quality of life. Dig Dis Sci 1995; 40: 584 – 9.en_US
dc.identifier.citedreferenceFischler B, Tack J, De Gucht V, et al. Heterogeneity of symptom pattern, psychosocial factors, and pathophysiological mechanisms in severe functional dyspepsia. Gastroenterology 2003; 124: 903 – 10.en_US
dc.identifier.citedreferenceChiba N, Bernard L, O'Brien BJ, Goeree R, Hunt RH. A Canadian physician survey of dyspepsia management. Can J Gastroenterol 1998; 12: 83 – 90.en_US
dc.identifier.citedreferenceStanghellini V, Tosetti C, Paternic A, et al. Risk indicators of delayed gastric emptying of solids in patients with functional dyspepsia. Gastroenterology 1996; 110: 1036 – 42.en_US
dc.identifier.citedreferenceTack J, Piessevaux H, Coulie B, Caenepeel P, Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology 1998; 115: 1346 – 52.en_US
dc.identifier.citedreferenceTalley NJ, Meineche-Schmidt V, Pare P, et al. Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 1055 – 65.en_US
dc.identifier.citedreferenceQuartero AO, de Wit NJ, Lodder AC, Numans ME, Smout AJ, Hoes AW. Disturbed solid-phase gastric emptying in functional dyspepsia: a meta-analysis. Dig Dis Sci 1998; 43: 2028 – 33.en_US
dc.identifier.citedreferencePerri F, Clemente R, Festa V, et al. Patterns of symptoms in functional dyspepsia: role of Helicobacter pylori infection and delayed gastric emptying. Am J Gastroenterol 1998; 93: 2082 – 8.en_US
dc.identifier.citedreferenceTalley NJ, Verlinden M, Jones M. Can symptoms discriminate among those with delayed or normal gastric emptying in dysmotility-like dyspepsia ? Am J Gastroenterol 2001; 96: 1422 – 8.en_US
dc.identifier.citedreferenceSarnelli G, Caenepeel P, Geypens B, Janssens J, Tack J. Symptoms associated with impaired gastric emptying of solids and liquids in functional dyspepsia. Am J Gastroenterol 2003; 98: 783 – 8.en_US
dc.identifier.citedreferencePallotta N, Pezzotti P, Calabrese E, Baccini F, Corazziari E. Relationship between gastrointestinal and extra-gastrointestinal symptoms and delayed gastric emptying in functional dyspeptic patients. World J Gastroenterol 2005; 11: 4375 – 81.en_US
dc.identifier.citedreferenceTalley NJ, Locke GR III, Lahr B, et al. Functional dyspepsia, delayed gastric emptying and impaired quality of life. Gut 2005; 55: 933 – 939.en_US
dc.identifier.citedreferenceDelgado-Aros S, Camilleri M, Cremonini F, Ferber I, Stephens D, Burton DD. Contributions of gastric volumes and gastric emptying to meal size and postmeal symptoms in functional dyspepsia. Gastroenterology 2004; 127: 1685 – 94.en_US
dc.identifier.citedreferenceKim DY, Delgado-Aros S, Camilleri M, et al. Noninvasive measurement of gastric accommodation in patients with idiopathic nonulcer dyspepsia. Am J Gastroenterol 2001; 96: 3099 – 105.en_US
dc.identifier.citedreferenceBoeckxstaens GE, Hirsch DP, Kuiken SD, Heisterkamp SH, Tytgat GN. The proximal stomach and postprandial symptoms in functional dyspeptics. Am J Gastroenterol 2002; 97: 40 – 8.en_US
dc.identifier.citedreferencePiessevaux H, Tack J, Walrand S, Pauwels S, Geubel A. Intragastric distribution of a standardized meal in health and functional dyspepsia: correlation with specific symptoms. Neurogastroenterol Motil 2003; 15: 447 – 55.en_US
dc.identifier.citedreferenceTack J, Bisschops R, Sarnelli G. Pathophysiology and treatment of functional dyspepsia. Gastroenterology 2004; 127: 1239 – 55.en_US
dc.identifier.citedreferenceSavoye G, Bouin M, Denis P, Ducrotte P. Delayed postprandial fundic relaxation: a new abnormal finding in functional dyspepsia. Scand J Gastroenterol 2005; 40: 354 – 5.en_US
dc.identifier.citedreferenceCamilleri M, Brown ML, Malagelada JR. Relationship between impaired gastric emptying and abnormal gastrointestinal motility. Gastroenterology 1986; 91: 94 – 9.en_US
dc.identifier.citedreferenceLin Z, Eaker EY, Sarosiek I, McCallum RW. Gastric myoelectrical activity and gastric emptying in patients with functional dyspepsia. Am J Gastroenterol 1999; 94: 2384 – 9.en_US
dc.identifier.citedreferenceJebbink HJ, van Berge-Henegouwen GP, Akkermans LM, Smout AJ. Small intestinal motor abnormalities in patients with functional dyspepsia demonstrated by ambulatory manometry. Gut 1996; 38: 694 – 700.en_US
dc.identifier.citedreferenceSimren M, Vos R, Janssens J, Tack J. Unsuppressed postprandial phasic contractility in the proximal stomach in functional dyspepsia: relevance to symptoms. Am J Gastroenterol 2003; 98: 2169 – 75.en_US
dc.identifier.citedreferenceMertz H, Fullerton S, Naliboff B, Mayer EA. Symptoms and visceral perception in severe functional and organic dyspepsia. Gut 1998; 42: 814 – 22.en_US
dc.identifier.citedreferenceRhee PL, Kim YH, Son HJ, et al. Evaluation of individual symptoms cannot predict presence of gastric hypersensitivity in functional dyspepsia. Dig Dis Sci 2000; 45: 1680 – 4.en_US
dc.identifier.citedreferenceTack J, Caenepeel P, Fischler B, Piessevaux H, Janssens J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology 2001; 121: 526 – 35.en_US
dc.identifier.citedreferenceBarbera R, Feinle C, Read NW. Abnormal sensitivity to duodenal lipid infusion in patients with functional dyspepsia. Eur J Gastroenterol Hepatol 1995; 7: 1051 – 7.en_US
dc.identifier.citedreferenceFeinle C, Meier O, Otto B, D'Amato M, Fried M. Role of duodenal lipid and cholecystokinin A receptors in the pathophysiology of functional dyspepsia. Gut 2001; 48: 347 – 55.en_US
dc.identifier.citedreferenceSamsom M, Verhagen MA, van Berge Henegouwen GP, Smout AJ. Abnormal clearance of exogenous acid and increased acid sensitivity of the proximal duodenum in dyspeptic patients. Gastroenterology 1999; 116: 515 – 20.en_US
dc.identifier.citedreferenceLadabaum U, Minoshima S, Hasler WL, Cross D, Chey WD, Owyang C. Gastric distention correlates with activation of multiple cortical and subcortical regions. Gastroenterology 2001; 120: 369 – 76.en_US
dc.identifier.citedreferenceVandenbergh J, Dupont P, Fischler B, et al. Regional brain activation during proximal stomach distention in humans: a positron emission tomography study. Gastroenterology 2005; 128: 564 – 73.en_US
dc.identifier.citedreferenceMearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129: 98 – 104.en_US
dc.identifier.citedreferenceSpiller RC. Inflammation as a basis for functional GI disorders. Best Pract Res Clin Gastroenterol 2004; 18: 641 – 61.en_US
dc.identifier.citedreferenceTack J, Demedts I, Dehondt G, et al. Clinical and pathophysiological characteristics of acute-onset functional dyspepsia. Gastroenterology 2002; 122: 1738 – 47.en_US
dc.identifier.citedreferenceDanesh J, Lawrence M, Murphy M, Roberts S, Collins R. Systematic review of the epidemiological evidence on Helicobacter pylori infection and nonulcer or uninvestigated dyspepsia. Arch Intern Med 2000; 160: 1192 – 8.en_US
dc.identifier.citedreferenceHall W, Buckley M, Crotty P, O'Morain CA. Gastric mucosal mast cells are increased in Helicobacter pylori -negative functional dyspepsia. Clin Gastroenterol Hepatol 2003; 1: 363 – 9.en_US
dc.identifier.citedreferenceHausken T, Svebak S, Wilhelmsen I, et al. Low vagal tone and antral dysmotility in patients with functional dyspepsia. Psychosom Med 1993; 55: 12 – 22.en_US
dc.identifier.citedreferenceHoltmann G, Goebell H, Jockenhoevel F, Talley NJ. Altered vagal and intestinal mechanosensory function in chronic unexplained dyspepsia. Gut 1998; 42: 501 – 6.en_US
dc.identifier.citedreferenceBerstad A. Functional dyspepsia – a conceptual framework. Gut 2000; 47 ( Suppl. 4 ): iv3 – 4; discussion iv10.en_US
dc.identifier.citedreferenceGeeraerts B, Vandenberghe J, Van Oudenhove L, et al. Influence of experimentally induced anxiety on gastric sensorimotor function in humans. Gastroenterology 2005; 129: 1437 – 44.en_US
dc.identifier.citedreferenceHsu PI, Lai KH, Lo GH, et al. Risk factors for ulcer development in patients with non-ulcer dyspepsia: a prospective two year follow up study of 209 patients. Gut 2002; 51: 15 – 20.en_US
dc.identifier.citedreferenceLieberman D, Fennerty MB, Morris CD, Holub J, Eisen G, Sonnenberg A. Endoscopic evaluation of patients with dyspepsia: results from the national endoscopic data repository. Gastroenterology 2004; 127: 1067 – 75.en_US
dc.identifier.citedreferenceFransen GA, Janssen MJ, Muris JW, Laheij RJ, Jansen JB. Meta-analysis: The diagnostic value of alarm symptoms for upper gastrointestinal malignancy. Aliment Pharmacol Ther 2004; 20: 1045 – 52.en_US
dc.identifier.citedreferenceJanssen HA, Muris JW, Knottnerus JA. The clinical course and prognostic determinants of non-ulcer dyspepsia: a literature review. Scand J Gastroenterol 1999; 34: 546 – 50.en_US
dc.identifier.citedreferenceNojkov B, Chey WD, Adlis S, Shaw M. Predictors of response to PPI therapy in patients with GERD: the influence of co-morbid IBS and psychological disease. Gastroenterology 2005; 128 ( Suppl. 2 ): A-61 (abstract).en_US
dc.identifier.citedreferenceFeinle-Bisset C, Vozzo R, Horowitz M, Talley NJ. Diet, food intake, and disturbed physiology in the pathogenesis of symptoms in functional dyspepsia. Am J Gastroenterol 2004; 99: 170 – 81.en_US
dc.identifier.citedreferenceBarbera R, Feinle C, Read NW. Nutrient-specific modulation of gastric mechanosensitivity in patients with functional dyspepsia. Dig Dis Sci 1995; 40: 1636 – 41.en_US
dc.identifier.citedreferenceSuzuki H, Masaoka T, Sakai G, Ishii H, Hibi T. Improvement of gastrointestinal quality of life scores in cases of Helicobacter pylori -positive functional dyspepsia after successful eradication therapy. J Gastroenterol Hepatol 2005; 20: 1652 – 60.en_US
dc.identifier.citedreferenceMalfertheiner P, Fischbach W, Layer P, et al. Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 2003; 18: 615 – 25.en_US
dc.identifier.citedreferenceGisbert JP, Cruzado AI, Garcia-Gravalos R, Pajares JM. Lack of benefit of treating Helicobacter pylori infection in patients with functional dyspepsia. Randomized one-year follow-up study. Hepatogastroenterology 2004; 51: 303 – 8.en_US
dc.identifier.citedreferenceVeldhuyzen van Zanten SJ, Fedorak RN, Lambert J, Cohen L, Vanjaka A. Absence of symptomatic benefit of lansoprazole, clarithromycin, and amoxicillin triple therapy in eradication of Helicobacter pylori positive, functional (nonulcer) dyspepsia. Am J Gastroenterol 2003; 98: 1963 – 9.en_US
dc.identifier.citedreferenceKoelz HR, Arnold R, Stolte M, Fischer M, Blum AL. Treatment of Helicobacter pylori in functional dyspepsia resistant to conventional management: a double blind randomised trial with a six month follow up. Gut 2003; 52: 40 – 6.en_US
dc.identifier.citedreferenceKoskenpato J, Farkkila M, Sipponen P. Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia. Am J Gastroenterol 2001; 96: 2866 – 72.en_US
dc.identifier.citedreferenceVeldhuyzen van Zanten SJ, Talley NJ, Blum AL, Bolling-Sternevald E, Sundin M, Junghard O. Combined analysis of the ORCHID and OCAY studies: does eradication of Helicobacter pylori lead to sustained improvement in functional dyspepsia symptoms ? Gut 2002; 50 ( Suppl. 4 ): iv26 – 30; discussion iv31–2.en_US
dc.identifier.citedreferenceMoayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2003; 1: CD002096.en_US
dc.identifier.citedreferenceLaine L, Schoenfeld P, Fennerty MB. Therapy for Helicobacter pylori in patients with nonulcer dyspepsia. A meta-analysis of randomized, controlled trials. Ann Intern Med 2001; 134: 361 – 9.en_US
dc.identifier.citedreferenceDanesh J, Pounder RE. Eradication of Helicobacter pylori and non-ulcer dyspepsia. Lancet 2000; 355: 766 – 7.en_US
dc.identifier.citedreferenceJaakkimainen RL, Boyle E, Tudiver F. Is Helicobacter pylori associated with non-ulcer dyspepsia and will eradication improve symptoms? A meta-analysis. BMJ 1999; 319: 1040 – 4.en_US
dc.identifier.citedreferenceLaheij RJ, Jansen JB, van de Lisdonk EH, Severens JL, Verbeek AL. Review article: Symptom improvement through eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. Aliment Pharmacol Ther 1996; 10: 843 – 50.en_US
dc.identifier.citedreferenceLaheij RJ, van Rossum LG, Verbeek AL, Jansen JB. Helicobacter pylori infection treatment of nonulcer dyspepsia: an analysis of meta-analyses. J Clin Gastroenterol 2003; 36: 315 – 20.en_US
dc.identifier.citedreferenceMoayyedi P, Soo S, Deeks J, et al. Eradication of Helicobacter pylori for non-ulcer dyspepsia. Cochrane Database Syst Rev 2005; 1: CD002096.en_US
dc.identifier.citedreferenceChey WD, Moayyedi P. Review article: Uninvestigated dyspepsia and non-ulcer dyspepsia-the use of endoscopy and the roles of Helicobacter pylori eradication and antisecretory therapy. Aliment Pharmacol Ther 2004; 19 ( Suppl. 1 ): 1 – 8.en_US
dc.identifier.citedreferenceGotthard R, Bodemar G, Brodin U, Jonsson KA. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988; 23: 7 – 18.en_US
dc.identifier.citedreferenceNyren O, Adami HO, Bates S, et al. Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986; 314: 339 – 43.en_US
dc.identifier.citedreferenceWeberg R, Aubert E, Dahlberg O, et al. Low-dose antacids or cimetidine for duodenal ulcer ? Gastroenterology 1988; 95: 1465 – 9.en_US
dc.identifier.citedreferenceMoayyedi P, Soo S, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev 2004; 4: CD001960.en_US
dc.identifier.citedreferenceMoayyedi P, Soo S, Deeks J, et al. Systematic review: Antacids, H2-receptor antagonists, prokinetics, bismuth and sucralfate therapy for non-ulcer dyspepsia. Aliment Pharmacol Ther 2003; 17: 1215 – 27.en_US
dc.identifier.citedreferenceRedstone HA, Barrowman N, Veldhuyzen van Zanten SJ. H2-receptor antagonists in the treatment of functional (nonulcer) dyspepsia: a meta-analysis of randomized controlled clinical trials. Aliment Pharmacol Ther 2001; 15: 1291 – 9.en_US
dc.identifier.citedreferenceAbraham NS, Moayyedi P, Daniels B, Veldhuyzen van Zanten SJ. Systematic review: the methodological quality of trials affects estimates of treatment efficacy in functional (non-ulcer) dyspepsia. Aliment Pharmacol Ther 2004; 19: 631 – 41.en_US
dc.identifier.citedreferenceMoayyedi P, Delaney BC, Vakil N, Forman D, Talley NJ. The efficacy of proton pump inhibitors in nonulcer dyspepsia: a systematic review and economic analysis. Gastroenterology 2004; 127: 1329 – 37.en_US
dc.identifier.citedreferenceMeineche-Schmidt V. Classification of dyspepsia and response to treatment with proton-pump inhibitors. Aliment Pharmacol Ther 2004; 20: 1171 – 9.en_US
dc.identifier.citedreferenceArts J, Caenepeel P, Verbeke K, Tack J. Influence of erythromycin on gastric emptying and meal related symptoms in functional dyspepsia with delayed gastric emptying. Gut 2005; 54: 455 – 60.en_US
dc.identifier.citedreferenceTalley NJ, Verlinden M, Snape W, et al. Failure of a motilin receptor agonist (ABT-229) to relieve the symptoms of functional dyspepsia in patients with and without delayed gastric emptying: a randomized double-blind placebo-controlled trial. Aliment Pharmacol Ther 2000; 14: 1653 – 61.en_US
dc.identifier.citedreferenceVeldhuyzen van Zanten SJ, Jones MJ, Verlinden M, Talley NJ. Efficacy of cisapride and domperidone in functional (nonulcer) dyspepsia: a meta-analysis. Am J Gastroenterol 2001; 96: 689 – 96.en_US
dc.identifier.citedreferenceHallerback BI, Bommelaer G, Bredberg E, et al. Dose finding study of mosapride in functional dyspepsia: a placebo-controlled, randomized study. Aliment Pharmacol Ther 2002; 16: 959 – 67.en_US
dc.identifier.citedreferenceKinoshita Y, Hashimoto T, Kawamura A, et al. Effects of famotidine, mosapride and tandospirone for treatment of functional dyspepsia. Aliment Pharmacol Ther 2005; 21 ( Suppl. 2 ): 37 – 41.en_US
dc.identifier.citedreferenceOtaka M, Jin M, Odashima M, et al. New strategy of therapy for functional dyspepsia using famotidine, mosapride and amitriptyline. Aliment Pharmacol Ther 2005; 21 ( Suppl. 2 ): 42 – 6.en_US
dc.identifier.citedreferencevan der Voort I, Schmidtmann M, Fach K, et al. Tegaserod improves gastric emptying and alters myoelectric activity in dyspeptic patients. Gastroenterology 2004; 126 ( Suppl. 2 ): A-643.en_US
dc.identifier.citedreferenceTack J, Vos R, Bisschops G, Tougas G, Janssens J, Phillipps T. Effect of tegaserod, a 5-HT 4 receptor agonist, on sensory and motor function of the proximal stomach in functional dyspepsia. Gastroenterology 2005; 128 ( Suppl. 2 ): A-94 (abstract).en_US
dc.identifier.citedreferenceTougas G, Chen Y, Luo D, Salter J, D'Elia T, Earnest D. Tegaserod improves gastric emptying in patients with gastroeparesis and dyspeptic symptoms. Gastroenterology 2003; 124 ( Suppl. 1 ): A-54 (abstract).en_US
dc.identifier.citedreferenceMearin F, Rodrigo L, Perez-Mota A, et al. Levosulpiride and cisapride in the treatment of dysmotility-like functional dyspepsia: a randomized, double-masked trial. Clin Gastroenterol Hepatol 2004; 2: 301 – 8.en_US
dc.identifier.citedreferenceHoltmann G, Talley NJ, Liebregts T, Adam B, Parow C. A placebo-controlled trial of itopride in functional dyspepsia. N Engl J Med 2006; 354: 832 – 40.en_US
dc.identifier.citedreferenceHojo M, Miwa H, Yokoyama T, et al. Treatment of functional dyspepsia with antianxiety or antidepressive agents: systematic review. J Gastroenterol 2005; 40: 1036 – 42.en_US
dc.identifier.citedreferenceDrossman DA, Toner BB, Whitehead WE, et al. Cognitive-behavioral therapy vs. education and desipramine vs. placebo for moderate to severe functional bowel disorders. Gastroenterology 2003; 125: 19 – 31.en_US
dc.identifier.citedreferenceDalton C, Diamant NE, Morris CB, et al. Are side effects of tricyclic antidepressants (TCAs) really side effects ? Gastroenterology 2004; 126 ( Suppl. 2 ): A-250.en_US
dc.identifier.citedreferenceMertz H, Fass R, Kodner A, Yan-Go F, Fullerton S, Mayer EA. Effect of amitriptyline on symptoms, sleep, and visceral perception in patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 160 – 5.en_US
dc.identifier.citedreferenceFioramonti J, Bueno L. Centrally acting agents and visceral sensitivity. Gut 2002; 51 ( Suppl. 1 ): i91 – 5.en_US
dc.identifier.citedreferenceGorelick AB, Koshy SS, Hooper FG, Bennett TC, Chey WD, Hasler WL. Differential effects of amitriptyline on perception of somatic and visceral stimulation in healthy humans. Am J Physiol 1998; 275 ( 3 Pt 1 ): G460 – 6.en_US
dc.identifier.citedreferenceTack J, Broekaert D, Coulie B, Fischler B, Janssens J. Influence of the selective serotonin re-uptake inhibitor, paroxetine, on gastric sensorimotor function in humans. Aliment Pharmacol Ther 2003; 17: 603 – 8.en_US
dc.identifier.citedreferenceLadabaum U, Glidden D. Effect of the selective serotonin reuptake inhibitor sertraline on gastric sensitivity and compliance in healthy humans. Neurogastroenterol Motil 2002; 14: 395 – 402.en_US
dc.identifier.citedreferenceTalley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996; 91: 277 – 83.en_US
dc.identifier.citedreferenceCalvert EL, Houghton LA, Cooper P, Morris J, Whorwell PJ. Long-term improvement in functional dyspepsia using hypnotherapy. Gastroenterology 2002; 123: 1778 – 85.en_US
dc.identifier.citedreferenceHaug TT, Wilhelmsen I, Svebak S, Berstad A, Ursin H. Psychotherapy in functional dyspepsia. J Psychosom Res 1994; 38: 735 – 44.en_US
dc.identifier.citedreferenceMine K, Kanazawa F, Hosoi M, Kinukawa N, Kubo C. Treating nonulcer dyspepsia considering both functional disorders of the digestive system and psychiatric conditions. Dig Dis Sci 1998; 43: 1241 – 7.en_US
dc.identifier.citedreferenceHamilton J, Guthrie E, Creed F, et al. A randomized controlled trial of psychotherapy in patients with chronic functional dyspepsia. Gastroenterology 2000; 119: 661 – 9.en_US
dc.identifier.citedreferenceSoo S, Forman D, Delaney BC, Moayyedi P. A systematic review of psychological therapies for nonulcer dyspepsia. Am J Gastroenterol 2004; 99: 1817 – 22.en_US
dc.identifier.citedreferenceThompson Coon J, Ernst E. Systematic review: Herbal medicinal products for non-ulcer dyspepsia. Aliment Pharmacol Ther 2002; 16: 1689 – 99.en_US
dc.identifier.citedreferenceMelzer J, Rosch W, Reichling J, Brignoli R, Saller R. Meta-analysis: Phytotherapy of functional dyspepsia with the herbal drug preparation STW 5 (Iberogast). Aliment Pharmacol Ther 2004; 20: 1279 – 87.en_US
dc.identifier.citedreferenceBortolotti M, Coccia G, Grossi G, Miglioli M. The treatment of functional dyspepsia with red pepper. Aliment Pharmacol Ther 2002; 16: 1075 – 82.en_US
dc.identifier.citedreferenceRodriguez-Stanley S, Collings KL, Robinson M, Owen W, Miner PB Jr. The effects of capsaicin on reflux, gastric emptying and dyspepsia. Aliment Pharmacol Ther 2000; 14: 129 – 34.en_US
dc.identifier.citedreferenceHoltmann G, Adam B, Haag S, Collet W, Grunewald E, Windeck T. Efficacy of artichoke leaf extract in the treatment of patients with functional dyspepsia: a six-week placebo-controlled, double-blind, multicentre trial. Aliment Pharmacol Ther 2003; 18: 1099 – 105.en_US
dc.identifier.citedreferenceRead NW, Abitbol JL, Bardhan KD, Whorwell PJ, Fraitag B. Efficacy and safety of the peripheral kappa agonist fedotozine vs. placebo in the treatment of functional dyspepsia. Gut 1997; 41: 664 – 8.en_US
dc.identifier.citedreferenceDelgado-Aros S, Chial HJ, Cremonini F, et al. Effects of asimadoline, a kappa-opioid agonist, on satiation and postprandial symptoms in health. Aliment Pharmacol Ther 2003; 18: 507 – 14.en_US
dc.identifier.citedreferenceStanghellini V, De Ponti F, De Giorgio R, Barbara G, Tosetti C, Corinaldesi R. New developments in the treatment of functional dyspepsia. Drugs 2003; 63: 869 – 92.en_US
dc.identifier.citedreferenceHolzer P. Acid-sensitive ion channels in gastrointestinal function. Curr Opin Pharmacol 2003; 3: 618 – 25.en_US
dc.identifier.citedreferenceHonore P, Mikusa J, Bianchi B, et al. TNP-ATP, a potent P2X3 receptor antagonist, blocks acetic acid-induced abdominal constriction in mice: comparison with reference analgesics. Pain 2002; 96: 99 – 105.en_US
dc.identifier.citedreferenceIde Y, Maehara Y, Tsukahara S, Kitahata LM, Collins JG. The effects of an intrathecal NMDA antagonist (AP5) on the behavioral changes induced by colorectal inflammation with turpentine in rats. Life Sci 1997; 60: 1359 – 63.en_US
dc.identifier.citedreferenceKuiken SD, Lei A, Tytgat GN, Holman R, Boeckxstaens GE. Effect of the low-affinity, noncompetitive N-methyl-D-aspartate receptor antagonist dextromethorphan on visceral perception in healthy volunteers. Aliment Pharmacol Ther 2002; 16: 1955 – 62.en_US
dc.identifier.citedreferenceKawabata A. Gastrointestinal functions of proteinase-activated receptors. Life Sci 2003; 74: 247 – 54.en_US
dc.identifier.citedreferenceKawabata A, Kinoshita M, Nishikawa H, et al. The protease-activated receptor-2 agonist induces gastric mucus secretion and mucosal cytoprotection. J Clin Invest 2001; 107: 1443 – 50.en_US
dc.identifier.citedreferenceWard SM, Bayguinov J, Won KJ, Grundy D, Berthoud HR. Distribution of the vanilloid receptor (VR1) in the gastrointestinal tract. J Comp Neurol 2003; 465: 121 – 35.en_US
dc.identifier.citedreferenceHolzer P. Gastrointestinal afferents as targets of novel drugs for the treatment of functional bowel disorders and visceral pain. Eur J Pharmacol 2001; 429: 177 – 93.en_US
dc.identifier.citedreferenceFoxx-Orenstein A, Camilleri M, Stephens D, Burton D. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003; 52: 1555 – 61.en_US
dc.identifier.citedreferenceMearadji B, Straathof JW, Biemond I, Lamers CB, Masclee AA. Effects of somatostatin on proximal gastric motor function and visceral perception. Aliment Pharmacol Ther 1998; 12: 1163 – 9.en_US
dc.identifier.citedreferenceMertz H, Walsh JH, Sytnik B, Mayer EA. The effect of octreotide on human gastric compliance and sensory perception. Neurogastroenterol Motil 1995; 7: 175 – 85.en_US
dc.identifier.citedreferenceFeinle C, Rades T, Otto B, Fried M. Fat digestion modulates gastrointestinal sensations induced by gastric distention and duodenal lipid in humans. Gastroenterology 2001; 120: 1100 – 7.en_US
dc.identifier.citedreferenceHolzer P, Holzer-Petsche U. Tachykinin receptors in the gut: physiological and pathological implications. Curr Opin Pharmacol 2001; 1: 583 – 90.en_US
dc.identifier.citedreferenceMonnikes H, Tebbe JJ, Hildebrandt M, et al. Role of stress in functional gastrointestinal disorders. Evidence for stress-induced alterations in gastrointestinal motility and sensitivity. Dig Dis 2001; 19: 201 – 11.en_US
dc.identifier.citedreferenceLiddle RA, Morita ET, Conrad CK, Williams JA. Regulation of gastric emptying in humans by cholecystokinin. J Clin Invest 1986; 77: 992 – 6.en_US
dc.identifier.citedreferenceMoran TH, McHugh PR. Cholecystokinin suppresses food intake by inhibiting gastric emptying. Am J Physiol 1982; 242: R491 – 7.en_US
dc.identifier.citedreferenceChua AS, Keeling PW, Dinan TG. Role of cholecystokinin and central serotonergic receptors in functional dyspepsia. World J Gastroenterol 2006; 12: 1329 – 35.en_US
dc.identifier.citedreferencePoli-Bigelli S, Rodrigues-Pereira J, Carides AD, et al. Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 2003; 97: 3090 – 8.en_US
dc.identifier.citedreferenceChawla SP, Grunberg SM, Gralla RJ, et al. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting. Cancer 2003; 97: 2290 – 300.en_US
dc.identifier.citedreferenceHill R. NK1 (substance P) receptor antagonists – why are they not analgesic in humans ? Trends Pharmacol Sci 2000; 21: 244 – 6.en_US
dc.identifier.citedreferenceSanger GJ. Neurokinin NK1 and NK3 receptors as targets for drugs to treat gastrointestinal motility disorders and pain. Br J Pharmacol 2004; 141: 1303 – 12.en_US
dc.identifier.citedreferenceDinan TG, Quigley EM, Ahmed SM, et al. Hypothalamic-pituitary-gut axis dysregulation in irritable bowel syndrome: plasma cytokines as a potential biomarker ? Gastroenterology 2006; 130: 304 – 11.en_US
dc.identifier.citedreferenceTache Y. Cyclic vomiting syndrome: the corticotropin-releasing-factor hypothesis. Dig Dis Sci 1999; 44 ( Suppl. 8 ): 79S – 86S.en_US
dc.identifier.citedreferenceChen CY, Inui A, Asakawa A, et al. Des-acyl ghrelin acts by CRF type 2 receptors to disrupt fasted stomach motility in conscious rats. Gastroenterology 2005; 129: 8 – 25.en_US
dc.identifier.citedreferenceLuckey A, Wang L, Jamieson PM, et al. Corticotropin-releasing factor receptor 1-deficient mice do not develop postoperative gastric ileus. Gastroenterology 2003; 125: 654 – 9.en_US
dc.identifier.citedreferenceTalley NJ, Van Zanten SV, Saez LR, et al. A dose-ranging, placebo-controlled, randomized trial of alosetron in patients with functional dyspepsia. Aliment Pharmacol Ther 2001; 15: 525 – 37.en_US
dc.identifier.citedreferenceDe Ponti F. Pharmacology of serotonin: what a clinician should know. Gut 2004; 53: 1520 – 35.en_US
dc.identifier.citedreferenceTack J, Talley NJ, Camilleri M, et al. Functional gastroduodenal disorders. Gastroenterology 2006; 130: 1466 – 79.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
j.1365-2036.2006.03005.x.pdf
Size:
181.8KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.